These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21797816)

  • 1. CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.
    Goodwin RS; Baumann MH; Gorelick DA; Schwilke E; Schwope DM; Darwin WD; Kelly DL; Schroeder JR; Ortemann-Renon C; Bonnet D; Huestis MA
    Am J Drug Alcohol Abuse; 2012 Jan; 38(1):114-9. PubMed ID: 21797816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonist-elicited cannabis withdrawal in humans.
    Gorelick DA; Goodwin RS; Schwilke E; Schwope DM; Darwin WD; Kelly DL; McMahon RP; Liu F; Ortemann-Renon C; Bonnet D; Huestis MA
    J Clin Psychopharmacol; 2011 Oct; 31(5):603-12. PubMed ID: 21869692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.
    Gorelick DA; Heishman SJ; Preston KL; Nelson RA; Moolchan ET; Huestis MA
    Am Heart J; 2006 Mar; 151(3):754.e1-754.e5. PubMed ID: 16504646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users.
    Huestis MA; Boyd SJ; Heishman SJ; Preston KL; Bonnet D; Le Fur G; Gorelick DA
    Psychopharmacology (Berl); 2007 Nov; 194(4):505-15. PubMed ID: 17619859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.
    Huestis MA; Gorelick DA; Heishman SJ; Preston KL; Nelson RA; Moolchan ET; Frank RA
    Arch Gen Psychiatry; 2001 Apr; 58(4):322-8. PubMed ID: 11296091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.
    Justinova Z; Munzar P; Panlilio LV; Yasar S; Redhi GH; Tanda G; Goldberg SR
    Neuropsychopharmacology; 2008 Nov; 33(12):2870-7. PubMed ID: 18305459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
    Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
    Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
    Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ
    Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
    Järbe TU; DiPatrizio NV
    Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL; McMahon LR
    J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
    Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
    Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.
    Järbe TU; Gifford RS; Makriyannis A
    Eur J Pharmacol; 2010 Dec; 648(1-3):133-8. PubMed ID: 20854804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents.
    Wade MR; Degroot A; Nomikos GG
    Eur J Pharmacol; 2006 Dec; 551(1-3):162-7. PubMed ID: 17030030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats.
    Newsom RJ; Osterlund C; Masini CV; Day HE; Spencer RL; Campeau S
    Neuroscience; 2012 Mar; 204():64-73. PubMed ID: 22138156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice.
    Roberts CJ; Stuhr KL; Hutz MJ; Raff H; Hillard CJ
    Pharmacol Biochem Behav; 2014 Feb; 117():17-24. PubMed ID: 24316201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
    Järbe TU; Li C; Vadivel SK; Makriyannis A
    Psychopharmacology (Berl); 2008 Jul; 198(4):467-78. PubMed ID: 18264696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.